Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple vs Sequential vs Concomitant Therapy for H. pylori
NCT02092506Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2011
- Primary completion
- Jun 2014
- Countries
- 1
- Sponsor
- Changi General Hospital
- Modality
- Small Molecules
- Conditions
- Helicobacter pylori infection
01
Overview
Phase 4, randomised, open-label trial of amoxicillin, clarithromycin and metronidazole in Helicobacter pylori infection (3 arms), sponsored by Changi General Hospital. Primary endpoint: H. pylori eradication rate. Started Dec 2011; status: completed.
02
Design
3 arms- Study design
- RandomizedOpen-label
Triple Therapy
PPI + Amoxicillin + Clarithromycin for 10 days
Sequential Therapy
PPI + Amoxicillin (5 days) -> PPI + Clarithromycin + Metronidazole (5 days)
Concomitant Therapy
PPI + Amoxicillin + Clarithromycin + Metronidazole for 10 days
03
Who it enrols
Consecutive patients newly diagnosed with H. pylori infection, excluding those with known allergies or previous therapy.
04
Endpoints
Primary
H. pylori eradication rate
Beyond the preview
Go deeper on NCT02092506.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092506.